Switch Strategies

Hear expert perspectives on when how and why to consider switching ART in virologically suppressed patients the single-tablet regimens long-acting injectables and more.

Share

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare